An interventional study of uniform dose radiotherapy and De-escalated dose radiotherapy in Prostate Cancer (Adenocarcinoma), sponsored by The Netherlands Cancer Institute. Recruiting at 1 site in Netherlands. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by The Netherlands Cancer Institute · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Prostatic Neoplasms by The Netherlands Cancer Institute — 6 open to participants now, 7 under way, none of them phase 3. Prostatic Neoplasms · The Netherlands Cancer Institute.
Among the 16 studies in Prostatic Neoplasms by The Netherlands Cancer Institute, this one is the 7th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2025, is one of 8 with no phase, and was the 16th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →6 of the 16 studies in Prostatic Neoplasms by The Netherlands Cancer Institute are open now, in 1 country. Recruiting first, the newest first:
The Netherlands Cancer Institute · Sites in Netherlands
Ages 18+
The Netherlands Cancer Institute · Sites in Netherlands
Ages 18+ · Men only
The Netherlands Cancer Institute · Sites in Netherlands
Ages 18+ · Men only
The Netherlands Cancer Institute · Sites in Netherlands
Ages 18+ · Men only
The Netherlands Cancer Institute
Ages 18+ · Men only
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 54 is close to the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 54 across the 13 interventional studies, 26 across the 3 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
The Netherlands Cancer Institute is the lead sponsor of 231 studies on the registry; 66 are open to participants now.
1 of the studies in Prostatic Neoplasms by The Netherlands Cancer Institute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07391982The Netherlands Cancer InstituteDose De-escalation in Prostate Radiotherapy Using an MR-Linac in Two Fractions | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Prostatic Neoplasms by The Netherlands Cancer Institute, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to find out whether lowering the radiation dose to parts of the prostate without visible tumor on MRI can reduce side effects while still effectively treating prostate cancer in men with low or intermediate-risk prostate cancer.
The main questions it aims to answer are:
Researchers will compare two treatment approaches:
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Radiation: uniform dose radiotherapy
Radiation: De-escalated dose radiotherapy
27 Gy dose in 2 fractions to the whole prostate+/- seminal vesicles with a 0mm PTV margin using MR-linac
The benign prostate +/- SV CTV will receive 20 Gy in 2 fractions with a 0mm PTV margin using MR-linac. The intraprostatic tumor masses (on MRI) will receive 27 Gy in 2 fractions. A 4mm GTV to PTV margin will be added to the in-traprostatic MR visible tumour to form PTV 27Gy.
Acute GU toxicity
Physician-reported acute Grade 2 or higher CTCAE GU toxicity observed within 13 weeks of starting radiotherapy
Time frame: within 13 weeks of starting radiotherapy
Dosimetry
Estimate the accumulated dose differences between treatment arms in terms of dose to prostate CTV, rectum, urethra and bladder
Time frame: During Radiotherapy treatment of 8 days
Late GI toxicity
Physician reported late GI toxicity according to CTCAE v5.0
Time frame: 1 and 2 years after radiotherapy treatment
Biochemical relapse-free survival
Assess biochemical relapse-free survival for 2 years
Time frame: 2 years
Severity of erectile dysfunction experienced by patient
The IIEF-5 patient reported outcomes (PROs) assess the acute severity of erectile dysfunction
Time frame: Before radiotherapy treatment, and at 6, 12 and 24 months after radiotherapy treatment
Acute GI toxicity
Physician reported acute GI toxicity according to CTCAE v5.0
Time frame: At baseline, after the last fraction, and 2, 4 and 12 weeks after radiotherapy treatment
Late GU toxicity
Physician reported late GU toxicity according to CTCAE v5.0
Time frame: 1 and 2 years after radiotherapy treatment
Late sexual toxicity
Physician reported late sexual toxicity according to CTCAE v5.0
Time frame: 1 and 2 years after radiotherapy treatment
Severity of urinary symptoms (GU) experienced by patient
The patient reported outcomes (PROs) International Prostate Symptoms Score (IPSS) assess the severity of urinary symptoms what the patient experiences
Time frame: Before radiotherapy treatment, after the last fraction, at 2, 4 and 12 weeks post-treatment, and at 6, 12 and 24 months after radiotherapy treatment
Health-related quality of life experienced by patient
The EPIC-26 patient reported outcomes (PROs) assess the health-related quality of life
Time frame: Before start radiotherapy, week 4 and week 12, at 6, 12 and 24 months after radiotherapy treatment.
Plan to share: Yes — It is intended that data will be shared within the MOMENTUM collaboration, between centres delivering treatment in the same way as DESTINATION2. Pseudonymised data will be stored within MOMENTUM for at least 5 years. Storage will be cloud based and as the treating centre we will have free access to the data and control over who else can assess it.
Time frame: 5 years
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Feb 2027, 15 months after the start.
Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 15 months is below that.
Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Netherlands Cancer Institute →